Please login to the form below
Zejula
This page shows the latest Zejula news and features for those working in and with pharma, biotech and healthcare.
NICE recommends GSK’s Zejula for patients with ovarian cancer
GlaxoSmithKline (GSK) has announced that the National Institute for Health and Care Excellence (NICE) has issued a Final Appraisal Determination (FAD) recommending the use of Zejula (niraparib) on the NHS. ... Zejula is recommended as a therapy option
Latest news
-
GSK’s PD-1 inhibitor dostarlimab shows updated promise in dMMR solid tumours
GSK gained dostarlimab from its $5.1bn acquisition of cancer specialist Tesaro, as well as PARP inhibitor Zejula (niraparib), which is approved across a number of indications including ovarian, fallopian tube
-
EU gives AZ’s Lynparza green light for BRCA-mutated pancreatic cancer
That includes GlaxoSmithKline’s (GSK) Zejula (niraparib) and Clovis Oncology’s Rubraca (rucaparib). ... GSK’s Zejula is more of a threat to Lynparza in the ovarian cancer market, with both companies revealing positive results for the respective
-
GlaxoSmithKline reportedly looking to sell select antibiotic brands
As a result of the Tesaro deal, GSK gained the rights to PARP inhibitor treatment Zejula, a particularly important drug in the company’s growing oncology portfolio. ... Although the PARP category is currently dominated by AstraZeneca and Merck
-
FDA accepts review to broaden GSK’s Zejula label
Seeks approval in advanced ‘all-comer’ ovarian cancer population. GlaxoSmithKline is on course to broaden the label of its PARP inhibitor Zejula, after announcing yesterday that the US Food and Drug ... GSK is seeking approval for Zejula (niraparib)
-
GSK pays $50m upfront to tap Immatics’ cell therapy platform
GSK took full ownership of the therapy in 2018. GSK’s push into cancer has also included its $5.1bn acquisition of Tesaro, which brought in PARP inhibitor Zejula (niraparib). ... Barron has said Zejula is one of three that he expects to drive the
More from news
Approximately 9 fully matching, plus 39 partially matching documents found.
Latest appointments
-
Rubius Therapeutics strengthens senior team
Prior to GSK, Dr Carpenter was at Merck, where he led the development of Tesaro’s Zejula.
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest from PMHub
-
World Ovarian Cancer Day: Current treatments and future hopes for ovarian cancer
11. European Medicines Agency. Zejula. Available at: https://www.ema.europa.eu/en/medicines/human/EPAR/zejula. Accessed April 2019.
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Country Manager, Healthcare Communications Agency, Germany
-
Highly competitive salary
- Sanofi halts recruitment for trials assessing MS treatment
- bluebird bio reveals plans to launch two gene therapies
- ONS data reveals significant decrease in COVID-19 antibodies
- AbbVie and Sosei Heptares collaborate in new agreement worth up to $1.2bn
- Eli Lilly to make bebtelovimab commercially available to US states from August
- ONS records a continued fall in UK COVID-19 infections
- Engaging KOLs and Gaining Insights in Pharma's New Normal
- That ‘don’t’ impress me much
- Bristol Myers Squibb and GentiBio in $1.9bn deal to develop IBD therapies
- Novartis’ Pluvicto receives MHRA marketing authorisation to treat advanced prostate cancer
- AstraZeneca and Daiichi Sankyo receive FDA approval for lung cancer drug
- ONS data reveals significant decrease in COVID-19 antibodies
PMHub
Viseven
Viseven is a Global MarTech Services Provider for Pharma and Life Sciences Industries...
Latest intelligence
- The communication challenge of helping he next generation to be healthier
- As the pressure on the health service increases the health of the next generation is vital for everyone. How do we show positive attitudes and change behaviour while future proofing...
- Are we losing sight of what the democratisation of healthcare really looks like?
- We have a core responsibility as healthcare communicators to consistently drive for better inclusion, engagement and compliance. What does the ‘democratisation of healthcare’ really look like?...
- How the Royal Society’s EiR programme can help to drive UK innovation
- ...
